Glaxo nabs FDA approval for hep C remedy Promacta

GlaxoSmithKline has won an FDA approval to market Promacta to hepatitis C patients whose low blood platelet counts prevent them from taking interferon, a commonly used treatment linked to a host of side effects. The approval marks a positive step for GSK ($GSK), which cited this R&D program as one of its most promising in the late-stage pipeline. And it significantly boosted shares of Ligand Pharmaceuticals ($LGND), which licensed the thrombocytopenia therapy to GSK back in 2008. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.